Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Eugenia Opolka-Hoffmann"'
Autor:
Anna Spreafico, Eva Muñoz Couselo, Anja Irmisch, Juliana Bessa, George Au-Yeung, Oliver Bechter, Inge Marie Svane, Miguel F. Sanmamed, Valentina Gambardella, Meredith McKean, Margaret Callahan, Reinhard Dummer, Christian Klein, Pablo Umaña, Nicole Justies, Florian Heil, Linda Fahrni, Eugenia Opolka-Hoffmann, Inja Waldhauer, Conrad Bleul, Roland F. Staack, Vaios Karanikas, Stephen Fowler
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
IntroductionAlthough checkpoint inhibitors (CPIs) have improved outcomes for patients with metastatic melanoma, those progressing on CPIs have limited therapeutic options. To address this unmet need and overcome CPI resistance mechanisms, novel immun
Externí odkaz:
https://doaj.org/article/1b6cf328c2214d24859fac4cbcd710e0
Autor:
Jerome Egli, Stefan Heiler, Felix Weber, Guido Steiner, Timo Schwandt, Katharine Bray-French, Christian Klein, Sebastian Fenn, Gregor P. Lotz, Eugenia Opolka-Hoffmann, Thomas E. Kraft, Laetitia Petersen, Rebecca Moser, Jonathan DeGeer, Michel Siegel, Daniela Finke, Juliana Bessa, Antonio Iglesias
Publikováno v:
mAbs, Vol 14, Iss 1 (2022)
Clinical anti-drug-antibody (ADA) responses represent a substantial obstacle to the development of efficacious therapeutic antibodies. The enhanced ADA production against the idiotype (Id) often displayed by cancer immunotherapy antibodies (CitAbs) c
Externí odkaz:
https://doaj.org/article/b365a7ae3054436e9a166bf9bbb165fe
Autor:
Eugenia Opolka-Hoffmann, Gregor Jordan, Michael Otteneder, Robin Kieferle, Martin Lechmann, Gerhard Winter, Roland F. Staack
Publikováno v:
mAbs, Vol 13, Iss 1 (2021)
The occurrence of an immune response against therapeutic proteins poses a major risk for the development of biologics and for successful treatment of patients. Generation of anti-drug antibodies (ADAs) can lead to formation of immune complexes (ICs),
Externí odkaz:
https://doaj.org/article/3020da09e9a14718ab04770201bfe6c1
Autor:
Roland F Staack, Robin Kieferle, Gerhard Winter, Eugenia Opolka-Hoffmann, Michael B. Otteneder, Martin Lechmann, Gregor Jordan
Publikováno v:
mAbs
article-version (VoR) Version of Record
article-version (VoR) Version of Record
The occurrence of an immune response against therapeutic proteins poses a major risk for the development of biologics and for successful treatment of patients. Generation of anti-drug antibodies (ADAs) can lead to formation of immune complexes (ICs),
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7017201216f6f842bd9cf0efa8596fea
https://doi.org/10.1080/19420862.2021.1995929
https://doi.org/10.1080/19420862.2021.1995929